SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

New RAMP 201 molecular-profiling and external-control analyses in recurrent low-grade serous ovarian cancer are drawing attention, especially signals of activity in KRAS wild-type patients that traders hope could broaden the treatment opportunity. Some see the data as supportive but not yet sufficient to move the share price, while discussion also centers on the upcoming VS-7375 clinical update.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and breakout are drawing momentum traders, with bullish chatter tying renewed interest to Starknets privacy and quantum-resistance narrative and Bitcoin DeFi plans such as strkBTC. Optimism about the technology and rising volume contrasts with concerns about token unlocks and whether the move can hold.

Pump.fun

A sharp rebound in PUMP has renewed bullish chatter, with traders citing Pump.funs buybacks, platform revenue and activity across the Solana memecoin ecosystem. Others question the rallys staying power and point to selloffs and weak discussion volume, leaving sentiment divided.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Bullish options flow and TSMCs move toward recent highs dominate discussion, alongside speculation about a potential Texas fab investment and early Terafab talks involving Elon Musk. Traders point to sustained AI-chip demand as support for the rally, while some caution about a possible technical pullback and the unconfirmed nature of the expansion reports.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Traders are positioning around Penguin Solutions earnings, weighing whether strong AI-infrastructure demand and backlog will translate into sales growth. Optimism about the AI and memory opportunity is countered by concerns that valuation is rich and the stocks run may invite profit-taking or shorting.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Reports that OpenAIs latest Ultrafast tier uses Nvidia GPUs rather than Cerebras hardware, alongside staged IPO share unlocks and insider selling, are weighing on the stock. Traders disagree over whether this signals a competitive setback or a temporary supply overhang, with bulls pointing to OpenAIs continued partnership and demand for Cerebras inference technology.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcoms reported Anthropic AI-infrastructure financing arrangement including up to $42 billion in convertible lending and a broader financing packagehas become the main focus. Traders are divided over whether it secures substantial demand for Broadcoms custom AI chips or creates customer-concentration and credit risks, amid continued frustration that the shares have lagged other semiconductor stocks.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Attention centers on Onyxs completed acquisition of Chains technology and IP, which traders see as a foundation for integrating payments, stablecoin and card services into its planned neobank. The community is bullish on the buildout and watching for further announcements, while skeptics question whether recent price strength can hold amid low volume and pump-and-dump concerns.

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Domestic Operations and International Operations segments. The company was founded on November 13, 2014 and is headquartered in Stamford, CT.

Curaleaf Holdings Inc

Traders are focused on a pause in the federal cannabis-rescheduling hearing, debating whether the procedural delay threatens or merely postpones the potential Schedule III change and related tax relief for cannabis operators. Curaleafs contested bid for Aurora is another prominent topic, with disagreement over the offers value and whether the deal will proceed.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnights mainnet launch and validator and institutional-adoption developments are drawing attention to NIGHTs privacy-focused network. Traders are optimistic about its use cases but debate whether ongoing token-thaw selling and weak volume will limit price momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: $LABT ) said in an October 1, 2026 release that Chief Executive Officer Kelvin Cooper, Ph.D., will participate in three industry conferences this month. The clinical-stage company is developing the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum antimicrobials for infectious diseases, and its lead candidate Nu-3 is a topical gel for infected diabetic foot ulcers. 
 
Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company&#39;s in-depth profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1 
 
Dr. Cooper&#39;s schedule moves from two New York City conferences, one featuring a company presentation, to presenting a poster on Nu-3 preclinical data at IDWeek in Washington, D.C.: 
• Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, during the October 13-14 event at the Hard Rock Hotel in New York City 
• At the ThinkEquity Conference on October 15 at The Mandarin Oriental Hotel in New York City, he will attend and give a 3:30 pm presentation on Nu-3 and its in vitro activity against resistant pathogens, for the treatment of infected diabetic foot ulcers 
• IDWeek runs October 21-24 at the Walter E. Washington Convention Center in Washington, D.C., with a hybrid format available, and he will present a poster on Nu-3 preclinical data there on October 22 
 
Across all three conferences, the company has opportunities to engage with members of the investment, biotechnology and infectious disease communities and to highlight its ongoing development programs in Bisphosphocin® antimicrobial technology. 
 
Read the full release: https://lakewoodamedex.investorroom.com/2026-10-01-Lakewood-Amedex-Biotherapeutics-Announces-Participation-in-October-Conferences 
 
Lakewood-Amedex Biotherapeutics, Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com. 
 
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. 
 
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. 
 
$SPRO, $CDTX, $SCYX, $XBI

J. Dionne

David Shapiro

fariha jabeen

Canesn83

Bonnie Siegmund

Ariana Storck

Linda Scott

Craig Salinas

Michael Musto

Roberta Creech

Eugene Davenport

Henry Callaghan

John Park

Shirley Hall

Melissa Vermillion

Micheal Fikes

Jeanne Hodges

James Adair

Kelly Distaffen

Nina Studdard

Renee Blankenship

Lucy Pena

Raymond Oliver

Filomena Marsh

Terry Skora

Amber Reilly

Edwina Packard

Lillian Ellis

Karen Paris

Ella Costello

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) is a clinical-stage biotech developing Bisphosphocin antimicrobials to fight drug-resistant infections.

B2idigital

Lakewood-Amedex Biotherapeutics Inc. | Nasdaq: LABT

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for...

Lakewood-Amedex Biotherapeutics Investors

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

Our novel approach fights infections with highly effective Bisphosphocins® directly at the site of infection. Bisphosphocins® directly disrupt microbial membranes, leading to fast eradication of infections.

Lakewoodamedex

Lakewood Amedex Biotherapeutics | Lakewood-Amedex Biotherapeutics | DEVELOPING SOLUTIONS FOR ANTIBIOTIC RESISTANCE CRISIS

b2i digital - connecting companies and investors through digital marketing, investor conferences, and direct introductions and meetings.

B2i Digital - Connecting companies and investors

Disclaimer - Content is provided "as is" by companies featured on the site. Conduct a trusted advisory before making investments.

Disclaimer - Consult an advisor before making any investments

StockTwits Web

Lakewood-Amedex Biotherapeutics Inc.

Spero Therapeutics Inc

Cidara Therapeutics Inc

Scynexis Inc

SPDR S&P Biotech ETF

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: 

 ) said in an October 1, 2026 release that Chief Executive Officer Kelvin Cooper, Ph.D., will participate in three industry conferences this month. The clinical-stage company is developing the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum antimicrobials for infectious diseases, and its lead candidate Nu-3 is a topical gel for infected diabetic foot ulcers. 
 
Lakewood-Amedex Biotherapeutics Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: 

 
 
Dr. Cooper's schedule moves from two New York City conferences, one featuring a company presentation, to presenting a poster on Nu-3 preclinical data at IDWeek in Washington, D.C.: 
• Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, during the October 13-14 event at the Hard Rock Hotel in New York City 
• At the ThinkEquity Conference on October 15 at The Mandarin Oriental Hotel in New York City, he will attend and give a 3:30 pm presentation on Nu-3 and its in vitro activity against resistant pathogens, for the treatment of infected diabetic foot ulcers 
• IDWeek runs October 21-24 at the Walter E. Washington Convention Center in Washington, D.C., with a hybrid format available, and he will present a poster on Nu-3 preclinical data there on October 22 
 
Across all three conferences, the company has opportunities to engage with members of the investment, biotechnology and infectious disease communities and to highlight its ongoing development programs in Bisphosphocin® antimicrobial technology. 
 
Read the full release: 

 
 
Lakewood-Amedex Biotherapeutics, Inc. (Nasdaq: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit 

. 
 
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at 

. 
 
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://

Lakewood-Amedex Biotherapeutics, Inc. is bringing its Bisphosphocin antimicrobial technology and Nu-3 development program to three major industry conferences this October, highlighting its work in infectious disease and antibiotic-resistant pathogens. 
 
As a B2i Digital Featured Company, explore Lakewood-Amedex Biotherapeutics, Inc.’s full profile at: https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1

Lakewood-Amedex Biotherapeutics, Inc. is bringing its Bisphosphocin antimicrobial technology and Nu-3 development program to three major industry conferences this October, highlighting its work in infectious disease and antibiotic-resistant pathogens. 
 
As a B2i Digital Featured Company, explore Lakewood-Amedex Biotherapeutics, Inc.’s full profile at: 